Cargando…
The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline
[Image: see text] A targeted bibliographic search exposed the deficiencies within existing PROTAC preclinical pipelines, including missing, poor-quality data and technical limitations in the experimental assays. Several recommendations are proposed to improve the efficiency of preclinical platforms...
Autores principales: | Apprato, Giulia, Ermondi, Giuseppe, Caron, Giulia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351046/ https://www.ncbi.nlm.nih.gov/pubmed/37465314 http://dx.doi.org/10.1021/acsmedchemlett.3c00231 |
Ejemplares similares
-
In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
por: Apprato, Giulia, et al.
Publicado: (2023) -
Are we ready to design oral PROTACs®?
por: Jimenez, Diego Garcia, et al.
Publicado: (2021) -
Rational Control of Molecular Properties Is Mandatory
to Exploit the Potential of PROTACs as Oral Drugs
por: Ermondi, Giuseppe, et al.
Publicado: (2021) -
PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery
por: Ermondi, Giuseppe, et al.
Publicado: (2021) -
Chamelogk:
A Chromatographic Chameleonicity Quantifier
to Design Orally Bioavailable Beyond-Rule-of-5 Drugs
por: Garcia Jimenez, Diego, et al.
Publicado: (2023)